Personalis NEOPRISM-CRC trial links early ctDNA clearance to colorectal cancer pCR

• Personalis highlighted clinical results already presented at AACR 2026 for its NeXT Personal blood test used to monitor treatment response and relapse risk across multiple cancer settings.
• Data from NEOPRISM-CRC indicated ctDNA-guided monitoring could help identify patients likely to fully respond to neoadjuvant immunotherapy versus those who may need a treatment change before surgery.
• Real-world evidence from 10,000 patients supported the assay’s ability to detect residual disease that less sensitive tests could miss, strengthening its competitive positioning in MRD testing.
• Personalis also introduced an opt-in Real-Time Variant Tracker feature that aims to follow emerging resistance mutations alongside MRD status, expanding clinical utility beyond recurrence monitoring.
• DARWIN 2 results in metastatic NSCLC suggested molecular clearance on NeXT Personal aligned with durable benefit on immunotherapy, supporting broader adoption in therapy monitoring workflows.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Personalis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202604210600BIZWIRE_USPR_____20260421_BW790003) on April 21, 2026, and is solely responsible for the information contained therein.